相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies
Darren Jun Hao Tan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)
Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments
Won-Mook Choi et al.
JOURNAL OF HEPATOLOGY (2022)
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
Darren Jun Hao Tan et al.
LANCET ONCOLOGY (2022)
Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis
Won-Mook Choi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir
Jung Woo Shin et al.
DIGESTIVE DISEASES AND SCIENCES (2021)
Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B
Te-Sheng Chang et al.
SCIENTIFIC REPORTS (2021)
Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants
Nicholas L. Syn et al.
LANCET (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
Hye Won Lee et al.
HEPATOLOGY INTERNATIONAL (2021)
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
Xinhui Wang et al.
GUT AND LIVER (2020)
Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China
Terry Cheuk-Fung Yip et al.
GASTROENTEROLOGY (2020)
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B
Yao-Chun Hsu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Survival Advantage of Laparoscopic Versus Open Resection For Colorectal Liver Metastases A Meta-analysis of Individual Patient Data From Randomized Trials and Propensity-score Matched Studies
Nicholas L. Syn et al.
ANNALS OF SURGERY (2020)
Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
Sung Won Lee et al.
GUT (2020)
No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir
Hyunwoo Oh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis
Min Li et al.
HEPATOLOGY INTERNATIONAL (2020)
Use of Propensity Score Methodology in Contemporary High-Impact Surgical Literature
Elysia Grose et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2020)
Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta -analysis of randomised clinical trials
Stephane Gaudry et al.
LANCET (2020)
Tenofovir Treatment Has Lower Risk of Hepatocellular Carcinoma than Entecavir Treatment in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis
Hairong Liu et al.
LIVER CANCER (2020)
Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
Yeonjung Ha et al.
SCIENTIFIC REPORTS (2020)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Theo Vos et al.
LANCET (2020)
Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
Ka Shing Cheung et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2020)
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis
Cheng-Hao Tseng et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis
Zeyu Zhang et al.
BMC CANCER (2019)
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in South Korea
Seung Up Kim et al.
JOURNAL OF HEPATOLOGY (2019)
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study
Jonggi Choi et al.
JAMA ONCOLOGY (2019)
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
Nafees Ahmad et al.
LANCET (2018)
Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
Eliana Rulli et al.
BRITISH JOURNAL OF CANCER (2018)
Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study
W. -K. Seto et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies
Xiaoxin I. Yao et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards
Hakim-Moulay Dehbi et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards
Hakim-Moulay Dehbi et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies
Xiaoxin I. Yao et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
S. K. Sarin et al.
HEPATOLOGY INTERNATIONAL (2016)
The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
Ioannis Varbobitis et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2016)
Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement
Lesley A. Stewart et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
George V. Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2015)
An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect
Patrick Royston et al.
TRIALS (2014)
A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis
Thomas P. A. Debray et al.
STATISTICS IN MEDICINE (2013)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt
Patrick Royston et al.
STATISTICS IN MEDICINE (2011)
Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses
Gloria Woo et al.
GASTROENTEROLOGY (2010)
Meta-analysis of individual participant data: rationale, conduct, and reporting
Richard D. Riley et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naive Patients Is Rare Through 5 Years of Therapy
Daniel J. Tenney et al.
HEPATOLOGY (2009)
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
CJ Chen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Comparison of evidence of treatment effects in randomized and nonrandomized studies
JPA Ioannidis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
分享论文
